Dapagliflozin in Allo-HCT for aGVHD
Dapagliflozin for Preventing Acute Graft-versus-Host Disease in Allogeneic Hematopoietic Cell Transplantation: A Prospective, Single-Arm Study
The First Affiliated Hospital of Soochow University
72 participants
Apr 26, 2025
INTERVENTIONAL
Summary
The goal of this clinical trial is to learn if Dapagliflozin could prevent acute graft-versus-host disease (aGVHD) in patients undergoing allogeneic hematopoietic cell transplantation (allo-HCT) with haploidentical or unrelated donor and to assess its safety. The main questions it aims to answer are: Dose Dapagliflozin lower the cumulative incidence of aGVHD? What medical problems do participants undergoing allo-HCT from haploidentical or unrelated donor have when taking Dapagliflozin? Researchers will document the occurrence of graft-versus-host disease, hematopoietic reconstitution, survival rates and adverse effects. Participants will take Dapagliflozin every day in -1 to 14 days.
Eligibility
Inclusion Criteria6
- Age 18 to 65 years old.
- Patients with hematologic malignancies indicated for allo-HCT and having a suitable haploidentical or unrelated donor.
- Willing to undergo myeloablative conditioning and graft-versus-host disease prophylaxis base on cyclosporin A and methotrexate.
- With Eastern Cooperative Oncology Group (ECOG) performance status of 0-3.
- Patients with prior use of Dapagliflozin or other hypoglycemic medications may switch to Dapagliflozin, contingent upon the treating physician's assessment of contraindications, will be eligible.
- Signing an informed consent form, having the ability to comply with study and follow-up procedures.
Exclusion Criteria9
- With other malignancies.
- With a previous history of autologous hematopoietic cell transplantation, allo-HCT or chimeric antigen receptor T-cell therapy.
- With a history of allergies to Dapagliflozin.
- With type 1 diabetes or a history of ketoacidosis.
- With a history of recurrent urinary tract infections.
- With severe organ dysfunction.
- With active hepatitis B virus, hepatitis C virus, or human immunodeficiency virus infection.
- In pregnancy or lactation period.
- With any conditions not suitable for the trial (investigators' decision).
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Participants will take Dapagliflozin 10mg every day in -1 to 14 days
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06626737